Cargando…

A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan

BACKGROUND: This study evaluated the safety and effectiveness of ramucirumab monotherapy and combination therapy for advanced gastric cancer in the real-world setting. METHODS: This single-arm, prospective, multicenter, non-interventional, observational, post-marketing study was conducted in Japan f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yucherng, Katayose, Taeko, Nagaoka, Soshi, Piao, Yongzhe, Yamaguchi, Kensei, Asou, Hiroya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502135/ https://www.ncbi.nlm.nih.gov/pubmed/34050432 http://dx.doi.org/10.1007/s10120-021-01199-0

Ejemplares similares

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2022)

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
por: Chen, Yucherng, et al.
Publicado: (2021)

Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial
por: Yamaguchi, Kensei, et al.
Publicado: (2020)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
por: Gao, Ling, et al.
Publicado: (2021)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2016)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
por: Rezvani, Hamid, et al.
Publicado: (2022)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
por: Mehta, Rutika, et al.
Publicado: (2020)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
por: Rakusic, Zoran, et al.
Publicado: (2020)

RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer
por: Sorokin, Maxim, et al.
Publicado: (2020)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database
por: Hirose, Naoki, et al.
Publicado: (2021)

Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study
por: Chin, Rina, et al.
Publicado: (2022)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study
por: Komatsu, Yoshito, et al.
Publicado: (2021)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
por: Urakawa, Shinya, et al.
Publicado: (2017)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Bronchobiliary fistula after ramucirumab treatment for advanced gastric cancer: A case report
por: Kim, Hong-Beum, et al.
Publicado: (2019)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report
por: Yang, Min Joo, et al.
Publicado: (2021)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

The dawn of precision medicine in diffuse-type gastric cancer
por: Ooki, Akira, et al.
Publicado: (2022)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3dr49hg8g967800uni3949klvs